(2,2-Dimethoxy-aethyl)-(4-methoxy-phenyl)-sulfid | 858816-12-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (2,2-Dimethoxy-aethyl)-(4-methoxy-phenyl)-sulfid
• 英文别名: (4-methoxy-phenylsulfanyl)-acetaldehyde dimethylacetal；(4-Methoxy-phenylmercapto)-acetaldehyd-dimethylacetal；1-(2,2-dimethoxyethylsulfanyl)-4-methoxybenzene；1-[(2,2-dimethoxyethyl)thio]-4-methoxybenzene；(2,2-Dimethoxyethyl)(4-methoxyphenyl)sulfane
• CAS: 858816-12-3
• 化学式: C₁₁H₁₆O₃S
• 分子量: 228.312
• InChiKey: AZEGDCRHWUYOOS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  53
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2,2-Dimethoxy-aethyl)-(4-methoxy-phenyl)-sulfid 在 丙酮 、 乙酸乙酯 、 Sodium sulfate-III 、 silica gel 、 hexanes 作用下， 以 盐酸 、 丙酮 为溶剂， 反应 2.0h， 以to afford the desired product (8.5 g, 97%)的产率得到(4-methoxyphenylthio)acetaldehyde
  参考文献：
  名称：

  IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS

  摘要：

  本发明涉及咪唑[1,2-b][1,2,4]三嗪和咪唑[1,2-a]嘧啶以及其制药组合物，它们是c-Met等激酶抑制剂，对于治疗癌症和与激酶通路失调相关的其他疾病有用。

  公开号：

  US20110136781A1
• 作为产物：
  描述：

  4-甲氧基苯硫酚 、 2-氯乙醛缩二甲醇 在 sodium methylate 作用下， 以 甲醇 、 5,5-dimethyl-1,3-cyclohexadiene 为溶剂， 生成 (2,2-Dimethoxy-aethyl)-(4-methoxy-phenyl)-sulfid
  参考文献：
  名称：

  Antitumor Agents. 284. New Desmosdumotin B Analogues with Bicyclic B-Ring as Cytotoxic and Antitubulin Agents

  摘要：

  We previously reported that the biological activity of analogues of desmosdumotin B (1) was dramatically changed depending on the B-ring system. A naphthalene B-ring analogue 3 exerted potent in vitro activity against a diverse panel of human tumor cell lines with GI(50) values of 0.8-2.1 mu M. In contrast, 1 analogues with a phenyl B-ring showed unique selective activity against P-glycoprotein (P-gp) over-expressing multidrug resistant cell line. We have now prepared and evaluated, 1 analogues with bicyclic or tricyclic aromatic B-ring systems as in vitro inhibitors of human cancer cell line proliferation. Among all synthesized derivatives, 21 with a benzo[b]thiophenyl B-ring was highly active, with GI(50) values of 0.06-0.16 mu M, and this activity was not influenced by overexpression of P-gp. Furthermore, 21 inhibited tubulin assembly in vitro with an IC(50) value of 2.0 mu M and colchicine binding by 7896 as well as cellular microtubule polymerization and spindle formation.

  DOI：

  10.1021/jm1011947

文献信息

• Novel Glucitol Derivative, Prodrug Thereof And Salt Thereof, And Therapeutic Agent Containing The Same For Diabetes
  申请人：Matsuoka Hiroharu

  公开号：US20080319047A1

  公开（公告）日：2008-12-25

  The invention provides a glucitol derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): wherein m is an integer selected among 1-3; R 1 to R 4 each independently is optionally substituted alkyl, etc.; Ar1 is optionally substituted naphthyl; and A is optionally substituted heteroaryl, a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, and the like each containing the compound.

  本发明提供了一种葡萄糖醇衍生物，具有降低血糖水平的功能，并具有药物所需的优良性质，例如持久的药物活性；以及用于预防或治疗由高血糖引起的疾病，例如糖尿病、糖尿病并发症和肥胖症的药物组合物。该衍生物是由式(I)表示的化合物：其中m是在1-3之间选择的整数；R1至R4各自独立地是可选的取代烷基等；Ar1是可选的取代萘基；A是可选的取代杂环芳基、该化合物的前药或其药学上可接受的盐。还提供了含有该化合物的药物、药物组合物等。
• Imidazotriazines and imidazopyrimidines as kinase inhibitors
  申请人：Incyte Corporation

  公开号：US07767675B2

  公开（公告）日：2010-08-03

  The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.

  本发明涉及咪唑并[1,2-b][1,2,4]三嗪和咪唑并[1,2-a]嘧啶，以及它们的药物组合物，它们是c-Met激酶抑制剂，可用于治疗与激酶通路失调相关的癌症和其他疾病。
• Glucitol derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：US07943748B2

  公开（公告）日：2011-05-17

  The invention provides a glucitol derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): wherein m is an integer selected among 1-3; R1 to R4 each independently is optionally substituted alkyl, etc.; Ar1 is optionally substituted naphthyl; and A is optionally substituted heteroaryl, a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, and the like each containing the compound.

  本发明提供了一种葡萄糖醇衍生物，具有降低血糖水平的功能，并具有药物所需的优良特性，例如长效药物活性；以及用于预防或治疗由高血糖引起的疾病，例如糖尿病、糖尿病并发症和肥胖症的药物组合物。该衍生物是由式（I）表示的化合物：其中m是在1-3之间选择的整数；R1到R4各自独立地是可选的取代烷基等；Ar1是可选的取代萘基；A是可选的取代杂环基，该化合物的前药物或其药学上可接受的盐。还提供了含有该化合物的药物、药物组合物等。
• NOVEL GLUCITOL DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：EP1803721A1

  公开（公告）日：2007-07-04

  The invention provides a glucitol derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): wherein m is an integer selected among 1-3; R1 to R4 each independently is optionally substituted alkyl, etc.; Ar1 is optionally substituted naphthyl; and A is optionally substituted heteroaryl, a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, and the like each containing the compound.

  本发明提供了一种葡萄糖醇衍生物，该衍生物具有降低血糖水平的功能，并具有药物所需的优越性能，如持久的药物活性；还提供了一种药物组合物，用于预防或治疗由高血糖引起的疾病，如糖尿病、糖尿病并发症和肥胖症。衍生物是由式 (I) 所代表的化合物： 其中 m 是选自 1-3 的整数；R1 至 R4 各自独立地是任选取代的烷基等；Ar1 是任选取代的萘基；A 是任选取代的杂芳基、该化合物的原药或二者的药学上可接受的盐。此外，还提供了各自含有该化合物的药物、药物组合物等。
• Imidazotriaines and imidazopyrimidines as kinase inhibitors
  申请人：Incyte Corporation

  公开号：US10738052B2

  公开（公告）日：2020-08-11

  The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.

  本发明涉及咪唑并[1,2-b][1,2,4]三嗪和咪唑并[1,2-a]嘧啶及其药物组合物，它们是激酶（如 c-Met）的抑制剂，可用于治疗癌症和其他与激酶通路失调有关的疾病。